Tom Powles: Phase 1b data with the HIF2a inhibitor casdatifan in clear cell patients
Tom Powles, Director of Barts Cancer Centre, shared a post on X:
“Phase 1b data with the HIF2a inhibitor casdatifan in clear cell patients is out. Good response rates with a low primary progression rate.
Adverse events look OK – anaemia and hypoxia.
PEAK1 is a new R3 study of cabozantinib +/- casdatifan in pretreated clear cell RCC.”
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre. With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023